Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Proof of Concept Study in Male and Female Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury

Next Previous
X
Search
Trial Profile

Proof of Concept Study in Male and Female Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solnatide (Primary)
  • Indications Acute lung injury; Pulmonary oedema
  • Focus Proof of concept; Therapeutic Use
  • Sponsors APEPTICO Forschung und Entwicklung

    • Most Recent Events

    • 28 Aug 2014 According to the European Clinical Trials Database record, status changed from active, no longer recruiting to completed.
    • 23 Aug 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2012-001863-64)
    • 09 Apr 2014 Topline results were reported in an Apeptico media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top